-Advertisement-
-Advertisement-
Hematology

Data from phase 3 study of leniolisib in APDS published
Results of a phase 3 clinical trial published in the journal Blood demonstrated the efficacy of the investigational drug leniolisib in patients with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. In the study, 31 patients with APDS were randomly assigned 2:1...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved